Small molecule · Inhibitor of fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3) · developed by Incyte
Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, FGFR2 and FGFR3, and inhibits FGFR4 at higher concentrations. It blocks constitutive FGFR signaling driven by activating fusions and amplifications, reducing malignant cell proliferation and survival. It is used in cholangiocarcinoma with FGFR2 rearrangement and in myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 9, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03914794 | Phase 2 | Bladder Cancer | Active not recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
FGFR2 Gene MutationFGFR2 Gene RearrangementIntrahepatic Cholangiocarcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →